Scott Wadsworth

Statistics

Publications

Citations

1.6K

H-Index

Active since

1984

Affiliations

Johnson & Johnson (United States)(Current)

Drug Discovery Laboratory (Norway)

Tulane University

Rutgers New Jersey Medical School

Rutgers, The State University of New Jersey

Scott Wadsworth is an author at Johnson & Johnson (United States) specializing in p38 mitogen-activated protein kinase signaling, life sciences, and cell signaling.

Publications per year

1984–2013

Publications

Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert, James R. Henry, John H. Dodd et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 252 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Interleukin (IL)-1 Receptor–associated Kinase (IRAK) Requirement for Optimal Induction of Multiple IL-1 Signaling Pathways and IL-6 Production

Palanisamy Kanakaraj, Peter Schäfer, Druie Cavender et al. · The Journal of Experimental Medicine · 1998 · 193 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

RWJ 67657, a Potent, Orally Active Inhibitor of p38 Mitogen-Activated Protein Kinase

Scott Wadsworth, Druie Cavender, Scott A. Beers et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 158 citations

Medicine, Immunology, Pharmacology +17

Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer

Lyndsay V. Rhodes, Sarah P. Short, Nicole F. Neel et al. · Cancer Research · 2010 · 152 citations · Full text

Medicine, Endocrinology, Oncology +17

6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (RWJ 68354): A Potent and Selective p38 Kinase Inhibitor

James R. Henry, Kenneth C. Rupert, John H. Dodd et al. · Journal of Medicinal Chemistry · 1998 · 77 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +5

1–5 of 26